Status:
UNKNOWN
Bexarotene Treatment in Schizophrenia
Lead Sponsor:
Beersheva Mental Health Center
Collaborating Sponsors:
Stanley Medical Research Institute
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-\[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl\] benzoic acid) on severity of psyc...
Eligibility Criteria
Inclusion
- age 18-60
- schizophrenia
- stable blood parameters
- normal baseline fasting triglyceride
- ability to sign informed consent
Exclusion
- lipid abnormalities
- leukopenia or neutropenia
- organic brain damage (mental retardation)
- alcohol or drug abuse
- renal disease
- hepatic dysfunction
- history of pancreatitis
- thyroid axis alterations
- suicide attempt in past year
- cataracts
- systemic treatment with more than 15,000IU vitamin A daily
- patients with known hypersensitivity to bexarotene or other components of the product
- pregnant women
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2006
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00141947
Start Date
September 1 2005
End Date
September 1 2006
Last Update
July 24 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beersheva Mental Health Center
Beersheva, Israel
2
Shaar Manashe Mental Health Center
Hadera, Israel